Eight cationic heteroleptic iridium(III) complexes, [Ir(epqc) 2 (N^N)] + , were prepared in high yield from a cyclometalated iridium bridged-chloride dimer bearing two ethyl-2-phenylquinoline-4-carboxylate (epqc) ligands. Two X-ray crystallographic studies were undertaken on selected complexes (where the ancillary ligand N^N = 4,4'-dimethyl-2,2'-bipyridine and 4,7-diphenyl-1,10-phenanthroline) each confirming the proposed formulations, showing an octahedral coordination at Ir(III). In general, the complexes are luminescent (620-630 nm) with moderately long lifetimes indicative of phosphorescence. Hydrolysis of the ethyl ester moieties of the epqc ligands gave the analogous cinchophen-based complexes, which were water-soluble and visibly luminescent (568-631 nm). The spectroscopic and redox characterisation of the complexes was complemented by DFT and TD-DFT calculations, supporting the assignment of dominant 3 MLCT to the emissive character. † Electronic supplementary information (ESI) available: Data collection parameters for the crystallographic studies, electrochemical data for 3a-h, pictorial representations of the calculated frontier orbitals for 3a-h and 4a-h and Cartesian coordinates obtained from DFT calculations. CCDC 907280 and 907282.
A series of substituted 2-phenylquinoxaline ligands have been explored to finely tune the visible emission properties of a corresponding set of cationic, cyclometallated iridium(III) complexes. The electronic and redox properties of the complexes were investigated through experimental (including time-resolved luminescence and transient absorption spectroscopy) and theoretical methods. The complexes display absorption and phosphorescent emissions in the visible region that are attributed to metal to ligand charge-transfer transitions. The different substitution patterns of the ligands induce variations in these parameters. Time-dependent DFT studies support these assignments and show that there is likely to be a strong spin-forbidden contribution to the visible absorption bands at λ=500-600 nm. Calculations also reliably predict the magnitude and trends in triplet emitting wavelengths for the series of complexes. The complexes were assessed as potential sensitisers in triplet-triplet annihilation upconversion experiments by using 9,10-diphenylanthracene as the acceptor; the methylated variants performed especially well with impressive upconversion quantum yields of up to 39.3 %.
Ten cationic heteroleptic iridium(III) complexes, [Ir(emptz)2(N^N)](PF6) were prepared from a cyclometalated iridium bridged-chloride dimer involving two ethyl-4-methylphenylthiazole-5-carboxylate (emptz) ligands. One X-ray crystallographic study was undertaken where the ancillary N^N ligand was 4,7-diphenyl-1,10-phenanthroline and revealed the anticipated structure, showing a distorted octahedral coordination geometry at Ir(III). The complexes were visibly luminescent with modestly structured emission at 540-590 nm and lifetimes (60-340 ns) consistent with phosphorescence. TD-DFT calculations suggest that strong MLCT character contributes to the visible absorption characteristics, whilst the moderately structured emission profiles indicate a (3)MLCT/(3)IL admixture of states to the phosphorescence.
Small-angle neutron scattering and contrast variation has been employed to quantify how a series of alcohols with increasing hydrophobicity exert different abilities to structure a model toluene based metallomicroemulsion - a microemulsion system stabilised with a metallosurfactant. Classical microemulsion phase evolution and droplet structure are observed, leading to an oil rich core stabilised by a surfactant film containing a highly concentrated, hydrated metal ion layer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.